Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

250P - FDG-PET/CT in high-risk primary breast cancer: A prospective study of stage migration and clinical impact

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Marianne Vogsen

Citation

Annals of Oncology (2020) 31 (suppl_4): S340-S347. 10.1016/annonc/annonc260

Authors

M. Vogsen1, J.D. Jensen1, I.Y. Christensen2, O. Gerke3, A.M.B. Jylling4, L.B. Larsen2, P. Braad3, K.L. Søe5, C. Bille5, M. Ewertz6, M.G. Hildebrandt3

Author affiliations

  • 1 Department Of Oncology, Odense University Hospital, 5000 - Odense/DK
  • 2 Department Of Radiology, Odense University Hospital, 5000 - Odense/DK
  • 3 Department Of Nuclear Medicine, Odense University Hospital, 5000 - Odense/DK
  • 4 Department Of Pathology, Odense University Hospital, 5000 - Odense/DK
  • 5 Department Of Breast Surgery, Odense University Hospital, 5000 - Odense/DK
  • 6 Department Of Clinical Research, University of Southern Denmark, 5000 - Odense/DK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 250P

Background

FDG-PET/CT remains an optional modality in primary breast cancer guidelines. Thus, we aimed to investigate the clinical impact of FDG-PET/CT for staging high-risk primary breast cancer.

Methods

Women with high-risk primary breast cancer were enrolled between September 2017 and August 2019 at Odense University Hospital, Denmark. Conventional with/without MRI mammography was performed prior to staging by FDG-PET/CT. We studied the accuracy of FDG-PET/CT for detection of distant metastases, the effect on change of treatment, and the prevalence of incidental findings. Biopsy and follow-up were used as reference standard for accuracy analysis.

Results

Of 103 women, 40 (38.8%) were upstaged to more advanced disease by FDG-PET/CT. Half of these, 24 (23%) were diagnosed with distant metastases and referred for medical non-curative treatment. Six-teen patients (16%) were upstaged to more advanced loco-regional disease, leading to more extensive radiotherapy. Among the 24 women with distant metastases, breast surgery could have been spared in six and was omitted in 18. Sensitivity and specificity for diagnosing distant metastases were 1.00 (95% confidence interval: 0.86-1.00) and 0.95 (0.88-0.99), respectively. Twenty-nine incidental findings were detected in 24 women (23%), leading to further examinations in 22 and diagnosis of eight (8/22, 36%) synchronous diseases: cancer (n=4), thyroiditis (n=2), aorta aneurysm (n=1) and meningioma (n=1).

Conclusions

FDG-PET/CT had substantial impact on staging and change of treatment in women with high-risk primary breast cancer, and further examination of incidental findings was considered clinically relevant. Our findings suggest that FDG-PET/CT should be considered for primary staging in high-risk primary breast cancer to improve treatment planning.

Clinical trial identification

NCT03358589.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Centre for Personalized Response Monitoring in Oncology (PREMIO), Odense University Hospital, Odense, Denmark Odense University Hospital University of Southern Denmark Astrid Thaysens grant Qvesehls Grant.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.